B-Lymphocyte Stimulator in Neuroendocrine Tumors: Correlation with Disease Behavior Abstract #404

Introduction: B-Lymphocyte Stimulator (BLyS) was recently involved in the regulation of malignant cell survival cancers.
Aim(s): To test BLyS as a new serological marker in the follow-up of patients with neuroendocrine tumors (NET).
Materials and methods: Eighty-one consecutive patients with NET and 56 sex-matched controls enrolled in the study. Patients were classified in two subgroups according to clinical course: evidence of persistent but stable disease or in remission (n=45) and patients with evidence of recurrent disease (n=36). BLyS and Chromogranin A (CgA) serum levels were analyzed by ELISA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Franco Grimaldi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#1032 Clinico-Biological and Histological Predictive Factors and Markers of Response to Everolimus in Neuroendocrine Tumors
Introduction: Several systemic treatments are available for metastatic neuroendocrine Tumors (NETs), including everolimus, but there is no predictive factor of response to these treatments.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Noura Benslama
#1044 Trends in Neuroendocrine Tumor in Friuli Venezia Giulia in the Last 20 Years
Introduction: Epidemiological study conducted on patients (pts) with neuroendocrine tumors (NEN) at the regional referral center for Endocrinology and Metabolic Diseases of the Udine Hospital, Italy.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof Franco Grimaldi
Keywords: survival
#1325 Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Franco Grimaldi
Authors: Grimaldi F, Motta C, Cipri C, Tonelli V, ...
Keywords: Tumor marker
#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Wim Meijer
Authors: Meijer W, Bruikman C, Beukeveld G, ...